Cambridge co. seeks FDA OK for cancer drug

Written By Unknown on Sabtu, 03 Mei 2014 | 18.38

A Cambridge company plans to seek federal regulatory approval this year for a new drug to treat pancreatic cancer after positive late-stage trial results were announced this week.

Merrimack Pharmaceuticals said its MM-398 drug, used in combination with two chemotherapy drugs, improved the average survival rate of patients with metastatic pancreatic cancer. The rate extended to 6.1 months — 1.9 months longer than when the other two drugs were used alone — for those who previously received gemcitabine-based therapy.

"Given that there have only been a handful of successful Phase 3 trials in pancreatic cancer in the past 25 years, it is gratifying to have the first positive Phase 3 trial in the post-gemcitabine setting," CEO Robert Mulroy said in a statement.

There are only three FDA-approved treatments for pancreatic cancer, which is the fourth leading cause of cancer death in the United States with a 6 percent five-year survival rate, according to the Pancreatic Cancer Action Network.

Shares of Merrimack fell 8 percent yesterday to $6.43, after soaring to a 52-week high of $7.65 on Thursday, when the company also reported a $27.8 million quarterly loss and said it has enough cash to get it into 2015.


Anda sedang membaca artikel tentang

Cambridge co. seeks FDA OK for cancer drug

Dengan url

http://sedangapasaja.blogspot.com/2014/05/cambridge-co-seeks-fda-ok-for-cancer.html

Anda boleh menyebar luaskannya atau mengcopy paste-nya

Cambridge co. seeks FDA OK for cancer drug

namun jangan lupa untuk meletakkan link

Cambridge co. seeks FDA OK for cancer drug

sebagai sumbernya

0 komentar:

Posting Komentar

techieblogger.com Techie Blogger Techie Blogger